Vecta Pharmaceuticals is developing an enhanced novel drug formulation for Symptomatic GERD

VCT111 is a unique, improved PPI (Proton Pump Inhibitor). VCT111 delivers superior efficacy and convenience over conventional PPI therapy. It offers daytime AND nighttime dosing flexibility and freedom from having to eat a meal to achieve therapeutic effect.

A dramatic improvement to existing PPI treatments

Nocturnal Relief

Daytime AND nighttime symptom relief

Superior PPI efficacy

 Clinical data shows enhanced effect of PPI therapy


Allows flexible dosing, including bedtime administration

Phase-III ready

Short time timeframe to market with clear expedited roadmap

VCT111 is undergoing clinical trials to gain FDA approval